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1. Introduction
Cysteine proteases represent attractive drug targets due to
their involvement in a wide variety of conditions such as 
cardiovascular, inflammatory, viral and immunological disorders 
and cancer.1 Methodology for controlling the activity of a 
disease-related cysteine protease may provide useful means for 
evaluating the protease as a drug target. In this context, caged 
cysteine proteases that release the parent proteases after exposure 
to UV light have been reported.2 Activity control of the proteases 
is enabled by UV-induced conversion of the “inactive” caged 
proteases to the “active” parent proteases. Recently, an advanced 
methodology which enables three-step activity control, such as 
“active (intact enzyme)” to “inactive (caging in living cells by 
addition of a caging reagent)” to “active (uncaging by UV-
irradiation),” was developed for enzymes other than cysteine 
proteases.3 To our knowledge, its application to cysteine 
proteases has yet to be reported. Therefore, we designed a catch-
and-release system for the advanced activity control of a cysteine 
protease as shown in Scheme 1. When a catch-and-release 
reagent possessing a recognition moiety for selective binding to 
the target protease and a warhead to react with an active center 
thiol is added to a proteome, the target cysteine protease is 
selectively caught by the reagent and is inactivated.4,5 If the 
catch-and-release reagent can be irreversibly removed by 
exposure to UV light, photo-induced re-activation of the protease 
is achieved. 
In this article, the design and synthesis of the UV-responsive 
catch-and-release reagent of thiols are described. Introduction of 
the recognition moiety on the reagent is also discussed. 
Scheme 1. Catch-and-release strategy for controlling the activity of cysteine 
proteases. 
2. Results and discussion
2.1. Design of catch-and-release reagent
We previously reported a stimulus-responsive amino acid6 that 
induced peptide bond cleavage after stimulus induced 
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deprotection followed by lactonization of the trimethyl lock 
moiety (Scheme 2).7 With this in mind, UV-responsive catch-
and-release reagent 1, composed of a trimethyl lock-like moiety 
and the UV-removable o-nitrobenzyl (oNB) group, was designed 
(Scheme 3). Compound 1 possesses an electron-deficient olefin 
moiety and a recognition moiety (R), therefore, it can recognize a 
target protease and react via Michael addition to generate the 
corresponding inactivated cysteine protease 2. After UV-induced 
removal of the o-nitrobenzyl group followed by lactonization of 
the trimethyl lock-like moiety, intermediate 3 should easily 
aromatize to release the parent cysteine protease. 
 
 
Scheme 2. Stimulus-responsive amino acid based on trimethyl lock system 
(PG: protective group removable by a stimulus).  
 
 
Scheme 3. Design of catch-and-release reagent for control of activity of 
cysteine protease.  
 
2.2. Synthesis of catch-and-release reagent 
Catch-and-release reagent 5 possessing a Boc-protected acyl 
hydrazine for facile introduction of the recognition moiety was 
synthesized as shown in Scheme 4. Phenol 68 was alkylated with 
o-nitrobenzyl bromide to afford ether 7. Knoevenagel 
condensation of 7 with sulfonylacetamide 10 derived from 
sulfanylacetic acid 8 was performed and catch-and-release 
reagent 5 was obtained. Because the geometry of compound 5 
could not be determined using NMR and X-ray methods, we 
synthesized easily crystallizable surrogate 11 and its geometry 
was determined to be (E) using X-ray crystallography (Scheme 
5). Therefore, we assumed that the geometry of 5 was also (E). 
 
 
Scheme 4. Reagents and conditions: (i) o-Nitrobenzyl bromide, K2CO3, 
CH2Cl2, 77%; (ii) H2N-NHBoc, O-(benzotriazol-1-yl)-N,N,N’,N’-
tetramethyluronium tetrafluoroborate (TBTU), N,N-diisopropylethylamine 
(DIEA), DMAP, CH2Cl2, 92%; (iii) Oxone®, MeOH/H2O, 0 °C to room 




Scheme 5. Reagents and conditions: (i) PhSO2CH2CO2Me, piperidine, AcOH, 
toluene, reflux, 83%. All hydrogen atoms of the X-ray structure of 11 are 
omitted for clarity. 
 
2.3. Catch-and-release experiment of  compound 5 
The catch-and-release reaction of a thiol with compound 5 
was examined. First, benzyl mercaptan was used as a thiol for 
simplicity (Scheme 6). Benzyl mercaptan was treated with 
compound 5 and Et3N in CH2Cl2, affording the Michael addition 
product 12 in 82% yield. After purification, caged thiol 12 was 
irradiated by UV (>365 nm) for 5 min, and the reaction mixture 
was shaken after addition of 2,2’-dithiodipyridine9 and Et3N. The 
reaction progress was monitored by HPLC (Fig. 1). After UV-
irradiation, the o-nitrobenzyl group of substrate 12 was 
completely removed to generate phenol 13. By the addition of 
2,2’-dithiodipyridine and Et3N followed by shaking for 2 h, 
intermediate 13 was successfully aromatized to release benzyl 
mercaptan derivative 14 and 4. The products were identified by 
ESI-MS and comparison of retention times with those of 
authentic samples.10 The synthesis of an authentic sample of 
compound 4 is depicted in Scheme 7. Briefly, after protection of 
phenol 6 with a methoxymethyl group followed by Knoevenagel 
condensation with commercially available phenylsulfonylacetic 
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acid methyl ester, obtained product 16 was treated with TFA to 
afford aromatized product 4. 
 
 
Scheme 6. Reagents and conditions: (i) Et3N, CH2Cl2, 82%; (ii) UV 
irradiation (>365 nm, 5 min) in MeOH followed by addition of 2,2’-
dithiodipyridine and Et3N. 
 
 
Fig. 1. HPLC profiles of photo-reaction of compound 12: (a) before UV-
irradiation, (b) after UV-irradiation (>365 nm, 5 min), (c) after UV-
irradiation (>365 nm, 3 min) followed by addition of 2,2’-dithiodipyridine 
and Et3N and shaking for 2 h. Analytical HPLC conditions: linear gradient of 
solvent B in solvent A, 50 to 80% over 30 min. Compounds eluted at 3-6 min 
are derivatives of photo-cleaved o-nitrobenzyl group. *2,2’-Dithiodipyridine. 
 
 
Scheme 7. Reagents and conditions: (i) Chloromethyl methyl ether, DIEA, 
CH2Cl2, 81%; (ii) PhSO2CH2CO2Me, AcOH, piperidine, toluene, reflux, 94%; 
(iii) TFA, CH2Cl2, 96%. 
 
Next, the catch-and-release reaction of a model peptide 
derived from a cysteine protease was examined. In this 
experiment, model peptide 1711 derived from the active site of 
caspase-912 was used, and each step of the catch-and-release 
reaction was monitored by HPLC (Scheme 8). In 
MeCN/phosphate buffer (pH 7.8), peptide 17 was treated with 
excess catch-and-release reagent 5, and caged peptide 18 was 
obtained after 24 h of incubation at 37 °C [Fig. 2 (a), (b)]. Next 
purified peptide 18 was irradiated by UV (>365 nm, 5 min), and 
the o-nitrobenzyl group of 18 was removed to generate phenol 19 
[Fig. 2 (c), (d)]. After 2 h of incubation at 37 °C in the presence 
of tris(2-carboxyethyl)phosphine (TCEP), release of caspase-9 
model peptide 17 occurred along with generation of aromatized 
product 4 as major products [Fig. 2 (e)].13 
These results suggest that compound 5 can potentially work as 
a prototype of a catch-and-release reagent for controlling the 
activity of cysteine proteases. 
 
#Scheme 8 and Fig. 2# see page 8. 
 
2.4. Introduction of recognition moiety onto catch-and-release 
reagent 
Introduction of a recognition moiety such as a substrate 
peptide sequence of a target protease to the catch-and-release 
reagent is of value for selective caging of the target protease in a 
proteome.4,5 Previously, one of the authors (K. A.) reported that a 
peptidyl substrate derivative of SARS cysteine protease (SARS 
3CLpro) possessing an aldehyde at the C-terminal position acted 
as a reversible inhibitor of SARS 3CLpro.14 Therefore, we decided 
to introduce catch-and-release reagent 5 onto the C-terminus of 
peptidyl substrates to control the activity of SARS 3CLpro 
(Scheme 9).15 Peptide conjugates 22 and 23 were synthesized as 
follows. After removal of the Boc group of 5, the obtained 
product was coupled with Boc-protected glutamine to generate 
compound 21. Then, the N-terminal Boc group was removed by 
acid treatment, and the obtained product was coupled with 
protected peptides 24 or 25, which were synthesized using 
standard Boc-based solution phase peptide synthesis. Finally, the 
obtained materials were subjected to global deprotection to 
generate peptide conjugates 22 and 23. Application of peptide 
conjugates 22 and 23 to control activity of SARS 3CLpro is 




Scheme 9. Reagents and conditions: (i) TFA then HCl/AcOEt; (ii) Boc-Q-
ONp, HOBt·H2O, Et3N, DMF, 85% (2 steps); (iii) TFA then HCl/AcOEt; (iv) 
24 (for 22) or 25 (for 23), EDC·HCl, HOBt·H2O, Et3N, DMF; (v) TFA, 
TMSBr, thioanisole, m-cresol, 0 °C. (A: alanine; L: leucine; Q: glutamine; R: 
arginine; S: serine; T: threonine; V: valine; Np = p-nitrophenyl) 
 
3. Conclusion 
In conclusion, a catch-and-release reagent for thiols was 
developed. By using this reagent, catch and UV-induced release 
of thiols including an active site model peptide of caspase-9 were 
achieved. Introduction of a peptidyl recognition moiety onto the 
reagent was also successful. We believe that these results 
represent an important step toward the development of catch-and-
release systems of cysteine proteases for controlling their 
activities. Application of the catch-and-release reagent to control 
activity of SARS 3CLpro is underway.  
4. Experimental section 
4.1. General methods 
All reactions were carried out under a positive pressure of argon 
except for UV-irradiation experiments and solid phase peptide 
synthesis. For column chromatography, Silica Gel 60 N (Kanto 
Chemical Co., Inc., spherical, neutral, particle size 63-210 μm) 
was employed. Exact mass spectra were recorded on a Waters 
Micromass® LCT PremierTM (ESI-TOF) or a Bruker Esquire200T 
(ESI-Ion Trap) spectrometer. NMR spectra were measured using 
a Bruker AV400N, a JEOL GSX400 or a JEOL GSX300 
spectrometer. For HPLC separation, a Cosmosil 5C18-AR-II 
analytical column (Nacalai Tesque, 4.6 × 250 mm, flow rate 1 
mL/min), a Cosmosil 5C18-AR-II semi-preparative column 
(Nacalai Tesque, 10 × 250 mm, flow rate 2.5 mL/min) or a 
Cosmosil 5C18-AR-II preparative column (Nacalai Tesque, 20 × 
250 mm, flow rate 10 mL/min) was employed, and eluting 
products were detected by UV at 220 nm. A solvent system 
consisting of 0.1% (v/v) TFA aqueous solution (solvent A) and 
0.1% (v/v) TFA in MeCN (solvent B) was used for HPLC elution. 
Photolysis by UV irradiation was performed using a Moritex 
MUV-202U with the filtered output (>365 nm) of a 3000 
mW/cm2 Hg-Xe lamp. Optical rotation was determined on a 
JASCO P-2200 polarimeter (concentration in g/100 mL).  
4.2. Synthesis of catch-and-release reagent 5 
4 .2 .1 .  2,4-Dimethy l-6 - (2-
n i trobenzyloxy)benzaldehyde (7 ) .  
To a stirred solution of phenol 68 (400 mg, 2.66 mmol) in 
DMF (13.0 mL) were added K2CO3 (1.44 g, 10.4 mmol) and o-
nitrobenzyl bromide (1.00 g, 4.60 mmol), and the resulting 
suspension was stirred at room temperature for 4 h. After 
addition of saturated aqueous solution of NH4Cl followed by 
stirring for 1 h, the mixture was extracted with AcOEt. The 
organic layer was washed with saturated aqueous solution of 
NH4Cl and brine, dried over Na2SO4, and concentrated in vacuo. 
The crude product was purified by column chromatography 
(hexane/AcOEt = 10:1 (v/v)) and 585 mg of benzaldehyde 7 
(2.05 mmol, 77%) was obtained as pale yellow needles; mp: 129-
130 °C; 1H NMR (CDCl3, 400 MHz) δ = 2.36 (3H, s), 2.58 (3H, 
s), 5.57 (2H, s), 6.71 (1H, s), 6.73 (1H, s), 7.54 (1H, t, J = 8.0 
Hz), 7.74 (1H, t, J = 8.0 Hz), 7.94 (1H, d, J = 8.0 Hz), 8.21 (1H, 
d, J = 8.0 Hz), 10.75 (1H, s); 13C NMR (CDCl3, 100 MHz) δ = 
21.5, 22.2, 67.3, 110.9, 121.1, 125.0, 125.8, 128.2, 128.5, 133.1, 
134.2, 1423, 145.9, 146.6, 161.4, 190.9; HRMS (ESI-TOF) m/z 
calcd for C16H16NO4 ([M + H]+) 286.1079, found 286.1090. Anal. 
calcd for C16H15NO4 C, 67.36; H, 5.30; N, 4.91, found C, 67.20; 
H, 5.24; N, 5.00. 
4.2 .2 .   N’ - (2-
Phenylsul fanylace tyl )hydrazinecarboxy l ic  acid  te r t -
butyl  es ter  (9 ) .  
To a solution of phenylthioacetic acid 8 (7.00 g, 41.6 mmol) 
in CH2Cl2 (100 mL) were added DMAP (460 mg, 3.70 mmol), 
HBTU (15.0 g, 39.5 mmol) and DIEA (6.88 mL, 39.5 mmol) at 
0 °C. The resulting mixture was stirred at room temperature for 
20 min, and tert-butyl carbazate (2.50 g, 37.8 mmol) was added 
to the reaction mixture at 0 °C. After being stirred at room 
temperature for 11 h, the resulting mixture was quenched by 
addition of H2O and extracted with CH2Cl2. The organic layer 
was washed with 5% (w/v) aqueous solution of citric acid, 5% 
(w/v) aqueous solution of NaHCO3 and brine, and was dried over 
Na2SO4. After concentration in vacuo, the crude product was 
purified by column chromatography (hexane/AcOEt = 2:1 (v/v)) 
and 9.83 g of sulfide 9 (34.8 mmol, 92%) was obtained as 
colorless oil: 1H NMR (CDCl3, 400 MHz) δ = 1.43 (9H, s), 3.69 
(2H, s), 6.40 (1H, br s), 7.22-7.26 (1H, m), 7.29-7.35 (2H, m), 
7.35-7.40 (2H, m), 8.27 (1H, br s); 13C NMR (CDCl3, 75 MHz) δ 
= 28.1, 36.2, 82.0, 127.0, 129.0, 129.3, 134.4, 155.1, 167.5; 
HRMS (ESI-TOF) m/z calcd for C13H18N2NaO3S ([M + Na]+) 
305.0936, found 305.0945. 
4.2 .3 .  N’ - (2-
Benzenesu l fony lace ty l )hydrazinecarboxy l ic  acid  
te r t -buty l  es ter  (10 ) .  
To a so lu t ion  of  su lf ide 9  (2 .13  g,  7 .56  mmol)  in  
MeOH/H2 O (1 :1  (v /v) ,  4 .0  mL) was  s lowl y added 
Oxone® (5 .11  g,  8 .31  mmol)  a t  0 °C, and the resulting 
mixture was stirred at room temperature for 15 h. The reaction 
mixture was extracted with CH2Cl2, and the organic layer was 
washed with brine, dried over Na2SO4 and concentrated in vacuo. 
The crude product was purified by column chromatography 
(hexane/AcOEt = 1:2 (v/v)) and 1.75 g of sulfone 10 (5.57 mmol, 
74%) was obtained as white powder; 1H NMR (CDCl3, 400 
MHz) δ = 1.47 (9H, s), 4.12 (2H, s), 6.73 (1H, br s), 7.58 (2H, dd, 
J = 7.6 and 7.5 Hz), 7.69 (1H, tt, J =7.5 and 1.1 Hz), 7.99 (2H, dd, 
J = 7.6 and 1.1 Hz), 8.71 (1H, br s); 13C NMR (CDCl3, 75 MHz) 
δ = 28.1, 60.5, 82.4, 128.5, 129.4, 134.5, 138.0, 155.1, 160.7; 
HRMS (ESI-TOF) m/z calcd for C13H18N2NaO5S ([M + Na]+) 
337.0834, found 337.0833. Anal. calcd for C13H18N2O5S C, 
49.67; H, 5.77; N, 8.91, found C, 49.39; H, 5.55; N, 8.85. 
4.2 .4 .  N’ -{2 -Benzenesul fonyl -3-[2 ,4-d imethyl -6- (2 -
n i trobenzyloxy)pheny l] -(E) -
acryloyl}hydrazinecarboxyl ic  ac id  te r t -butyl  es ter  
(5 ) .  
Piperidine (52.0 μL, 531 μmol) and AcOH (60.0 μL, 1.06 
mmol) were added to a solution of sulfone 10 (1.84 g, 5.85 
mmol) and aldehyde 7 (1.50 g, 5.31 mmol) in toluene (60.0 mL). 
After refluxing for 18 h, H2O was added to the reaction mixture 
at room temperature. The mixture was extracted with AcOEt, and 
the organic layer was washed with H2O and brine, dried over 
Na2SO4 and concentrated in vacuo. The crude product was 
purified by column chromatography (hexane/AcOEt = 3:1 (v/v)) 
and 2.62 g of catch-and-release reagent 5 (4.50 mmol, 85%) was 
obtained as pale yellow amorphousness; 1H NMR (CDCl3, 400 
MHz) δ = 1.35 (9H, s), 2.30 (3H, s), 2.78 (3H, s), 5.45 (2H, s), 
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6.30 (1H, br s), 6.60 (1H, s), 6.71 (1H, s), 7.45 (1H, td, J = 7.6 
and 1.2 Hz), 7.49-7.59 (3H, m), 7.62 (1H, tt, J = 7.6 and 1.2 Hz), 
7.71 (1H, d, J = 7.6 Hz), 8.03 (2H, dd, J = 7.6 and 1.2 Hz), 8.23 
(1H, s), 8.27 (1H, d, J = 4.0 Hz); 13C NMR (CDCl3, 75 MHz) δ = 
20.1, 21.8, 27.9, 67.2, 81.8, 110.8, 118.1, 124.4, 124.8, 128.3, 
128.4, 128.5, 129.2, 133.4, 133.7, 134.1, 136.7, 138.4, 139.4, 
141.9, 142.8, 146.6, 154.1, 154.9, 159.7; HRMS (ESI-TOF) m/z 
calcd for C29H31N3NaO8S ([M + Na]+) 604.1730, found 604.1746. 
4.2 .5 .  2-Benzenesul fonyl -3-[2 ,4 -d imethyl -6- (2 -
n i trobenzyloxy)pheny l] -(E) -acryl ic  acid  methyl  
es ter  (11 ) .  
Piperidine (5.0 μL, 40 μmol) and AcOH (5.0 μL, 87 μmol) 
were added to a solution of aldehyde 7 (110 mg, 0.396 mmol) 
and phenylsulfonylacetic acid methyl ester (99.0 mg, 0.462 
μmol) in toluene (4.00 mL). The reaction mixture was refluxed 
for 17 h and was quenched by addition of H2O at room 
temperature. The resulting mixture was extracted with AcOEt, 
and the organic layer was washed with H2O and brine, dried over 
Na2SO4, and concentrated in vacuo. The crude product was 
purified by column chromatography (hexane/AcOEt = 4:1 (v/v)) 
and 152 mg of compound 11 (0.320 mmol, 83%) was obtained as 
colorless prisms. Recrystallized material from Et2O was brought 
to X-ray analysis; mp: 129-130 °C; 1H NMR (CDCl3, 400 MHz) 
δ = 2.32 (6H, s), 3.40 (3H, s), 5.33 (2H, s), 6.63 (1H, s), 6.75 (1H, 
s), 7.30 (1H, t, J = 7.6 Hz), 7.40 (1H, t, J = 7.6 Hz), 7.49 (1H, d, 
J = 7.6 Hz), 7.51 (2H, t, J = 7.6 Hz), 7.65 (1H, t, J = 7.6 Hz), 
8.01 (2H, d, J = 7.6 Hz), 8.10 (1H, d, J = 7.6 Hz), 8.33 (1H, s); 
13C NMR (CDCl3, 100 MHz) δ = 20.1, 21.8, 52.0, 67.4, 110.9, 
118.7, 124.5, 124.7, 128.1, 128.2, 128.5, 128.8, 132.7, 133.2, 
133.9, 136.1, 138.6, 140.5, 1419, 143.5, 146.2, 155.0, 162.3; 
HRMS (ESI-TOF) m/z calcd for C25H24NO7S ([M + H]+) 
482.1273, found 482.1273. Anal. calcd for C25H23NO7S C, 62.36; 
H, 4.81; N, 2.91, found C, 62.13; H, 4.79; N, 2.99. 
4.3. Catch and release experiment of compound 5 
4 .3 .1 .  Michae l  addi t ion  o f  benzyl  mercaptan.  
To a solution of catch-and-release reagent 5 (40.0 mg, 69.7 
μmol) in CH2Cl2 (700 μL) were added benzyl mercaptan (60.0 
μL, 510 μmol) and Et3N (71.0 μL, 510 μmol) with additional 
stirring at room temperature for 6 h. After addition of H2O, the 
mixture was extracted with CH2Cl2. The organic layer was dried 
over Na2SO4 and concentrated in vacuo. The crude product was 
purified by column chromatography (hexane/AcOEt = 4:1 (v/v)) 
and 40.0 mg of diastereomeric mixture 12  (56.6 μmol, 82%) was 
obtained as colorless amorphousness. 1H NMR (CDCl3, 400 MHz, 
peaks derived form a major isomer was depicted) δ = 1.50 (9H, s), 
1.83 (3H, s), 2.09 (3H, s), 3.78 (1H, d, J = 13.1 Hz), 3.94 (1H, d, 
J = 13.1 Hz), 4.74 (1H, d, J = 11.2 Hz), 5.02 (2H, s), 5.30 (1H, d, 
J = 11.2 Hz), 5.76 (1H, s), 6.46 (1H, s), 7.00 (1H, br s), 7.13-7.20 
(2H, m), 7.20-7.30 (6H, m), 7.38 (2H, d, J = 7.3 Hz), 7.48 (1H, tt, 
J = 7.6 and 1.2 Hz), 7.72 (1H, t, J = 7.6 Hz), 7.95 (1H, d, J = 7.6 
Hz), 8.15 (1H, dd, J = 8.0 and 1.0 Hz), 8.25 (1H, br s); HRMS 
(ESI-TOF) m/z calcd for C36H39N3NaO8S2 ([M + Na]+) 728.2076, 
found 728.2053. 
4.3 .2 .  UV-ir radia t ion  experiment  o f  compound 12 .  
Compound 12 (33 μg, 0.47 μmol) in MeOH (100 μL) was 
irradiated by UV (>365 nm) for 5 min. To the reaction mixture 
were added 2,2’-dithiodipyridine (200 μg, 0.90 μmol) and Et3N 
(5.0 μL, 35 μmol) at 0 °C, and the obtained mixture was shaken 
at room temperature for 2 h. Progress of the reaction was 
monitored by analytical HPLC. Analytical HPLC conditions: 
linear gradient of solvent B in solvent A, 50 to 80% over 30 min. 
Retention time: 12, 29.3 and 29.8 min; 13, 16.8 and 17.1 min; 4, 
13.4 min; 14, 12.5 min. Intermediate 13 was identified by LRMS 
(ESI-TOF) m/z calcd for [M + H]+ 571.2, found 571.2 
(diastereomeric mixture). Compounds 4 and 14 were identified 
by RLMS and comparison of retention time with that of authentic 
samples. 4: LRMS (ESI-TOF) m/z calcd for [M + H]+ 315.1, 
found 315.2. 1410: LRMS (ESI-TOF) m/z calcd for [M + H]+ 
234.0, found 234.2. 
4.3 .3 .  Caspase-9  model  pept ide (17 ) .  
The protected peptidyl resin was manually constructed using 
Fmoc-based solid phase peptide synthesis on NovaSyn® TGR 
resin (loading: 0.25 mmol/g). Fmoc-protected amino acid 
derivatives (3 equiv.) were successively condensed using N,N’-
diisopropylcarbodiimide (3 equiv.) in the presence of HOBt·H2O 
(3 equiv.) in DMF for 2 h. The following side-chain protective 
groups were used: Trt for cysteine and glutamine, tBu for 
glutamic acid, and Boc for lysine. Fmoc group was removed by 
treatment of the resin with 20% (v/v) piperidine in DMF for 10 
min. The completed resin (41.0 mg) was treated with 
TFA/thioanisole/m-cresol/1,2-ethanedithiol/Et3SiH/H2O 
(80:5:5:2.5:2.5:5 (v/v), 2.0 mL) at room temperature for 2 h. 
After filtration, cooled Et2O was added to the filtrate, and the 
resulting precipitate was collected by centrifugation. The 
obtained precipitate was washed with Et2O and purified by 
preparative HPLC to give model peptide 17 (1.0 mg, 10%). 
Analytical HPLC conditions: linear gradient of solvent B in 
solvent A, 1 to 80% over 30 min. Retention time: 13.0 min. 
Preparative HPLC conditions: linear gradient of solvent B in 
solvent A, 0 to 30% over 60 min. LRMS (ESI-Ion Trap) m/z 
calcd for [M + H]+ 1242.6, found 1242.8. 
4.3 .4 .  Michae l  addi t ion  o f  mode l  pept ide 17  
To a solution of model peptide 17 (2.00 mg, 1.60 μmol) in 
sodium phosphate buffer (pH 7.8, 50 mM phosphate, 2.0 mL) 
was added catch-and-release reagent 5 (4.00 mg, 6.87 μmol) in 
MeCN (2.0 mL). After incubation at 37 °C followed by HPLC 
purification, peptide conjugate 18 (0.78 mg, 28%) was obtained 
as a diastereomeric mixture. Analytical HPLC conditions: linear 
gradient of solvent B in solvent A, 10 to 95% over 30 min. 
Retention time: 16.9, 17.2 or 17.4 min, respectively for each 
diastereomer. Semi-preparative HPLC conditions: linear gradient 
of solvent B in solvent A, 29 to 39% over 30 min. LRMS (ESI-
TOF) m/z calcd for [M + 2H]2+ 912.4, found 912.1, 912.1 or 
912.1, respectively.  
4.3 .5 .  UV-ir radia t ion  experiment  o f  compound 18  
A solution of glutathione (reduced form, 0.25 M, 8.0 μL) in 
MeCN (100 μL) was added to compound 18 (0.10 mg, 10 μmol) 
in sodium phosphate buffer (pH 7.8, 50 mM phosphate, 2 mM 
EDTA, 92 μL), and the resulting mixture was irradiated by UV 
(>365 nm) for 5 min. After addition of an aqueous solution of 
TCEP·HCl (0.10 M, 30 μL), the reaction solution was incubated 
at 37 °C and the reaction progress was monitored by analytical 
HPLC. Analytical HPLC conditions: linear gradient of solvent B 
in solvent A, 10 to 95% over 30 min. Retention time: 19, 17.1 or 
17.3 min, respectively for each diastereomer; 4, 25.0 min; 17, 
10.9 min. LRMS (ESI-Ion Trap) of diastereomeric mixture of 
intermediate 19: m/z calcd for [M + H]+ 1688.7, found 1688.5. 
4.3 .6 .  2-Methoxymethoxy-4 ,6 -d imethylbenzaldehyde 
(15 ) .  
To a stirred solution of phenol 68 (95.0 mg, 0.633 mmol) in 
CH2Cl2 (5.00 mL) were added chloromethyl methyl ether (127 
mg, 1.58 mmol) and DIEA (0.550 mL, 3.15 mmol), and the 
resulting mixture was stirred at room temperature for 23 h. The 
reaction was quenched with 5% (w/v) aqueous solution of 
NaHCO3 at 0 °C and the resulting mixture was extracted with 
Et2O. The organic layer was washed with brine, dried over 
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Na2SO4 and concentrated in vacuo. The crude product was 
purified by column chromatography (hexane/AcOEt = 4:1 (v/v)) 
and 99.0 mg of aldehyde 15 (0.510 mmol, 81%) was obtained as 
colorless oil. 1H NMR (CDCl3, 400 MHz) δ = 2.34 (3H, s), 2.55 
(3H, s), 3.52 (3H, s), 5.26 (2H, s), 6.69 (1H, s), 6.86 (1H, s), 
10.61 (1H, s); 13C NMR (CDCl3, 100 MHz) δ = 21.4, 22.0, 56.3, 
94.5, 112.8, 121.4, 126.0, 141.6, 145.5, 160.9, 191.4; HRMS 
(ESI-TOF) m/z calcd for C11H14NaO3 ([M + Na]+) 217.0841, 
found 217.0835. 
4.3 .7 .  2-Benzenesul fonyl -3- (2 -methoxymethoxy-4 ,6-
d imethylphenyl )acryl ic  acid  methyl  es ter  (16 ) .  
Piperidine (2.0 μL, 200 μmol) and AcOH (2.0 μL, 35 μmol) 
were added to a solution of aldehyde 15 (90.0 mg, 463 μmol) and 
phenylsulfonylacetic acid methyl ester (97.0 mg, 453 μmol) in 
toluene (5.00 mL). The resulting mixture was refluxed for 22 h 
and was quenched by addition of H2O at room temperature. The 
mixture was extracted with AcOEt, and the organic layer was 
washed with H2O and brine, dried over Na2SO4 and concentrated 
in vacuo. The crude product was purified by column 
chromatography (hexane/AcOEt= 4:1 (v/v)) and 170 mg of 
acrylate 16 (435 μmol, 94%) was obtained as pale yellow oil; 1H 
NMR (CDCl3, 400 MHz) δ = 2.31 (3H, s), 2.32 (3H, s), 3.19 (3H, 
s), 3.57 (3H, s), 4.93 (2H, s), 6.73 (1H, s), 6.74 (1H, s), 7.54 (2H, 
t, J = 7.2 Hz), 7.61 (1H, t, J = 7.2 Hz), 8.01 (2H, d, J = 7.2 Hz), 
8.17 (1H, s); 13C NMR (CDCl3, 100 MHz) δ = 20.1, 21.6, 51.9, 
56.1, 94.5, 112.8, 119.1, 124.7, 128.2, 128.6, 133.1, 135.8, 138.6, 
140.4, 141.8, 142.3, 154.1, 162.7; HRMS (ESI-TOF) m/z calcd 
for C20H22NaO6S ([M + Na]+) 413.1035, found 413.1049. 
4.3 .8 .  3-Benzenesul fonyl -5 ,7 -d imethylchromen-2 -
one (4 ) .  
To a solution of acrylate 16 (49.0 mg, 125 μmol) in CH2Cl2 
(1.00 mL) was added TFA (1.00 mL), and the resulting mixture 
was stirred at room temperature for 2 h. After addition of H2O, 
the mixture was extracted with CH2Cl2. The organic layer was 
dried over MgSO4 and concentrated in vacuo, and 39.0 mg of 
compound 4 (120 μmol, 96%) was obtained as yellow solid; 1H 
NMR (CDCl3, 400 MHz) δ = 2.43 (3H, s), 2.61 (3H, s), 6.99 (1H, 
s), 7.03 (1H, s), 7.55 (2H, t, J = 7.6 Hz), 7.63 (1H, t, J = 7.6 Hz), 
8.14 (2H, d, J = 7.6 Hz), 8.93 (1H, s); 13C NMR (CDCl3, 75 
MHz) δ = 18.4, 22.1, 114.1, 115.1, 128.0, 128.9, 129.0, 129.3, 
134.0, 138.8, 144.3, 144.4, 147.3, 155.1, 156.4; HRMS (ESI-
TOF) m/z calcd for C17H15O4S ([M + H]+) 315.0691, found 
315.0698. 
 
4.4. Introduction of recognition moiety 
4 .4 .1 .  General  procedures  for  Boc-based  so lu t ion  
phase pept ide synthes is .  
Deprotection  procedure A: A substrate was treated with TFA 
(5 to 10 mL/g substrate) for 1.5 h at 0 °C. After evaporation, 
HCl/AcOEt (4 M, 4 equiv.) was added to the residues and the 
mixture was stirred for 3 min and concentrated in vacuo. The 
obtained residue was dried over KOH pellets under reduced 
pressure. 
Deprotection procedure B: A substrate was treated with TFA 
(5 to 10 mL/g substrate) for 1.5 h at 0 °C. After evaporation, the 
obtained residue was dried over KOH pellets under reduced 
pressure. 
Purification procedure A: A material soluble in AcOEt was 
extracted with AcOEt and the extract was washed successively 
with 5% (w/v) aqueous solution of NaHCO3 and brine, dried over 
Na2SO4, and concentrated under reduced pressure. 
Purification procedure B: A material insoluble in AcOEt was 
precipitated by the addition of an appropriate solvent. The 
resulting solid was filtered, washed successively with 5% (w/v) 
aqueous solution of citric acid, 5% (w/v) aqueous solution of 
NaHCO3 and H2O, and dried in vacuo. 
4.4 .2 .  [(1S )-1 - (N'- {2-Benzenesu l fonyl -3 -[2 ,4-
d imethyl -6 -(2 -n i trobenzyloxy)pheny l] -(E )-
acryloyl}hydrazinocarbonyl) -3 -
carbamoylpropyl] carbamic ac id  t er t-butyl  es ter  
(21 ) .  
Compound 5 (2.00 g, 3.43 mmol) was subjected to 
deprotection procedure A. To solution of the resulting residue in 
DMF (10 mL), Et3N (947 μL, 6.80 mmol), Boc-Q-ONp (1.25 g, 
3.43 mmol) and HOBt·H2O (701 mg, 3.43 mmol) were added at 
0 °C. The reaction mixture was stirred at room temperature for 
4.5 h. After concentration in vacuo, the resulting residue was 
subjected to purification procedure A and the obtained material 
was purified by column chromatography (CHCl3/MeOH = 19:1 
(v/v)) and 2.06 g of compound 21 (2.90 mmol, 85%) was 
obtained as colorless amorphousness; [α]17D -16.7 (c 1.02, 
CHCl3); 1H NMR (CDCl3, 400 MHz) δ = 1.37 (9H, s), 1.70-1.90 
(2H, m), 2.06-2.18 (2H, m), 2.67 (6H, s), 4.02-4.16 (1H, br m), 
5.38 (1H, d, J = 15.4 Hz), 5.42 (1H, d, J = 15.4 Hz), 5.50 (1H, d, 
J = 7.6 Hz), 6.00 (1H, br s), 6.37 (1H, br s), 6.60 (1H, s), 6.68 
(1H, s), 7.44 (1H, t, J = 8.0 Hz), 7.46-7.55 (3H, m), 7.58 (1H, tt, 
J = 7.2 and 1.2 Hz), 7.67 (1H, d, J = 7.6 Hz), 7.97 (2H, d, J = 7.6 
Hz), 8.08 (1H, dd, J = 8.0 and 1.2 Hz), 8.21 (1H, s), 8.74 (1H, br 
s), 9.96 (1H, br s); 13C NMR (CDCl3, 75 MHz) δ = 20.0, 21.6, 
28.2, 29.2, 31.3, 51.7, 66.9, 80.0, 110.7, 117.8, 124.2, 124.6, 
128.1, 128.3, 128.4, 129.1, 133.2, 133.6, 133.9, 136.4, 138.6, 
139.4, 142.0, 146.6, 155.1, 155.7, 159.1, 169.6, 175.6; HRMS 
(ESI-TOF) m/z calcd for C34H39N5NaO10S ([M + Na]+) 732.2315, 
found 732.2339. 
4.4 .3 .  Synthes is  o f  pept ide conjugate  22  and  23  
Typical procedure. Compound 21 (94.3 mg, 133 μmol) was 
treated with TFA (1 mL) at 0 °C for 1.5 h. After evaporation, 
HCl/AcOEt (4 M, 200 μL) was added to the residue at 0 °C. The 
mixture was stirred at same temperature for 3 min, and then 
evaporated. The obtained residue was dissolved in DMF (1 mL), 
and to the solution were added Et3N (38 μL, 273 μmol), peptide 
24 (100 mg, 140 μmol), HOBt·H2O (29 mg, 140 μmol) and 
EDC·HCl (27 mg, 140 μmol) at 0 °C. The reaction mixture was 
stirred at room temperature overnight. After concentration in 
vacuo, the resulting residue was subjected to purification 
procedure B and reprecipitation from DMF/AcOEt to give 119 
mg of the protected catch-and-release reagent (91.2 mmol, 70%) 
as white powder. Then, the product (50.0 mg, 383 μmol) was 
treated with TMSBr (215 μL), thioanisole (192 μL), m-cresol 
(81.1 μL) and TFA (1.21 mL) at 0 °C for 1.5 h. To the resulting 
mixture was added cooled Et2O and the generated precipitate was 
collected by centrifugation. The precipitate was washed with 
Et2O and purified by preparative HPLC to give 12.3 mg of 
peptide conjugate 22 (10.9 μmol, 29%). Protected precursor of 
compound 22: LRMS (ESI-Ion Trap) m/z calcd for [M + K]+ 
1341.5, found 1341.6. Protected precursor of compound 23: 
LRMS (ESI-Ion Trap) m/z calcd for [M + H]+ 1464.6, found 
1464.6. Compound 22: Analytical HPLC conditions: linear 
gradient of solvent B in solvent A, 30 to 80% over 30 min. 
Preparative HPLC conditions: linear gradient of solvent B in 
solvent A, 40 to 50%. LRMS (ESI-Ion Trap) m/z calcd for [M + 
H]+ 1123.5, found 1123.8. Compound 23: Analytical HPLC 
conditions: linear gradient of solvent B in solvent A, 30 to 80% 
over 30 min. Preparative HPLC conditions: linear gradient of 
solvent B in solvent A, 37 to 47%. LRMS (ESI-Ion Trap) m/z 
calcd for [M + 2H]+ 596.8, found 597.0.  
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4.4 .4 .  Synthes is  o f  pro tec ted  pept ide 24 .  
To a solution of H-L-OPac (prepared from Boc-L-OPac16 
(2.00 g, 5.72 mmol) according to deprotection procedure A. Pac: 
phenacyl), Et3N (1.67 mL, 12.0 mmol), Boc-V-OH (1.37 g, 6.29 
mmol) and HOBt·H2O (1.30 g, 6.29 mmol) in DMF (20 mL), 
EDC·HCl (1.21 g, 6.29 mmol) was added at 0 °C. The reaction 
mixture was stirred at room temperature overnight. After 
concentration in vacuo, the resulting residue was subjected to 
purification procedure A, and reprecipitation form hexane to give 
1.30 g of Boc-VL-OPac (2.89 mmo, 46%). 
Boc protected amino acids were coupled onto Boc-VL-OPac 
(1.30 g, 2.89 mmol) as similar to that described above. Procedure 
and yield are summarized below. 
Boc-A-OH: Deprotection of substrate = procedure A; 
purification = procedure B; reprecipitation form AcOEt; 85% 
yield. 
Boc-S(Bzl)-OH: deprotection of substrate = procedure A; 
purification = procedure B; reprecipitation from CHCl3/Et2O; 
89% yield. 
Boc-T(Bzl)-OH: deprotection of substrate = procedure A; 
purification = procedure B; reprecipitation form CHCl3/Et2O; 
80% yield. 
To a solution of TFA·H-T(Bzl)S(Bzl)AVL-OPac (prepared 
from Boc-T(Bzl)S(Bzl)AVL-OPac (350 mg, 338 μmol) 
according to deprotection procedure B) in pyridine/DMF (1:1 
(v/v), 4 mL) was added Ac2O (319 μL, 3.38 mmol). The reaction 
mixture was stirred at room temperature overnight. After 
concentration in vacuo, the resulting residue was subjected to 
purification procedure B and reprecipitation from DMF/AcOEt to 
give 226 mg of Ac-T(Bzl)S(Bzl)AVL-OPac (272 μmol, 81%). It 
was suspended in AcOH/DMF (9:1 (v/v), 3.50 mL), and Zn dust 
(356 mg, 5.44 mmol) was added to the suspension. After stirring 
the mixture at room temperature for 3 h followed by filtration, 
the filtrate was concentrated in vacuo. The residue was subjected 
to purification procedure B and reprecipitation form DMF/AcOEt 
to give 170 mg of peptide 24 (238 μmol, 88%)) as white powder; 
LRMS (ESI-Ion Trap) m/z calcd for [M + H]+ 712.4, found 712.4. 
4.4 .5 .  Synthes is  o f  pro tec ted  pept ide 25 .  
To a solution of Boc-R(Mts)-OH (3.15 g, 6.29 mmol) in THF 
(20 mL) were added isobutyl chloroformate (816 μL, 6.29 mmol) 
and Et3N (1.67 mL, 12.0 mmol) at -21 °C, and the reaction 
mixture was stirred at same temperature for 20 min. The resulting 
mixture was added to a solution of TFA·H-L-OPac (prepared 
from Boc-L-OPac16 (2.00 g, 5.72 mmol) according to 
deprotection procedure B) in DMF at 0 °C. After overnight 
reaction at room temperature, the solution was concentrated in 
vacuo. The product was subjected to purification procedure A 
and reprecipitation from Et2O to give 2.51 g of Boc-R(Mts)L-
OPac (3.64 mmol, 64%). 
Boc protected amino acids were coupled onto Boc-R(Mts)L-
OPac (2.40 g, 3.49 mmol) as similar to that described in Section 
4.4.4. Procedure and yield are summarized below. 
Boc-V-OH: deprotection of substrate = procedure A; 
purification = procedure A; reprecipitation form hexane; 97% 
yield. 
Boc-T(Bzl)-OH: deprotection of substrate = procedure A; 
purification = procedure B; reprecipitation from AcOEt/hexane; 
84% yield. 
Boc-A-OH: deprotection of substrate = procedure A; 
purification = procedure B; reprecipitation form Et2O; 95% yield. 
Acetyl capping and removal of Pac group were performed as 
similar to that described in Section 4.4.4. Acetyl cap: 
deprotection procedure B; purification procedure B; 
reprecipitation from DMF/AcOEt; 93% yield. Removal of Pac 
group: purification procedure B; reprecipitation from 
DMF/AcOEt; 82% yield; LRMS (ESI-Ion Trap) m/z calcd for [M 
+ H]+ 873.5, found 873.5. 
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Scheme 8. Reagents and conditions: (i) MeCN/phosphate buffer (pH 7.8) = 1:1 (v/v), 37 °C; (ii) UV irradiation (>365 nm, 5 min) in MeCN/phosphate buffer (pH 
7.8) = 1:1 (v/v) containing glutathione and EDTA followed by incubation at 37 °C in the presence of TCEP. (A: alanine; C: cysteine; E: glutamic acid; F: 




Fig. 2. HPLC profiles of catch-and-release reaction of compound 5. Michael addition of peptide 17 to compound 5: (a) 0 h, (b) 24 h. UV-irradiation experiment 
of compound 18: (c) before UV-irradiation, (d) after UV-irradiation (>365 nm, 5 min), (e) after UV-irradiation (>365 nm, 5 min) followed by incubation at 37 °C 
in the presence of TCEP for 2 h. Analytical HPLC conditions: linear gradient of solvent B in solvent A, 10 to 95% over 30 min. *Glutathione. **Non-peptidyl 
compound. 
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